SunBio,Inc., a biotech company, (067370) Fair Value & Analysis
Healthcare · KR · Market cap 69.6B KRW
Fair value as of: Jul 20, 2026
From 24 valuation models · updated 21 days ago
Share price +13.3% over the past month.
A solid business, but screening 30% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (5,741 KRW). The favourable scenario is already priced in.
- Solid but not exceptional quality (58/100) and above fair value, neither a clear bargain nor a standout compounder.
- A fairly wide model range (2,812 KRW to 5,741 KRW) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 20, 2026.
How to read this chart
60‑month range 4,945 KRW – 37,733 KRW · fair‑value band 2,812 KRW – 5,741 KRW · the 6,580 KRW price screens above the 4,593 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 20, 2026.
Analysis
SunBio,Inc., a biotech company, (067370) currently trades at 6,580 KRW, while our model-based Fair Value estimate is 4,593 KRW, implying the stock looks roughly 30.2% overvalued today. The Quality Score stands at 58/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, SunBio,Inc., a biotech company, generated revenue of 2.2B KRW at a net margin of 64.2%. It earns a return on equity of 35.4%. Net debt stands at 25.7B KRW. Fundamentals as of Jul 20, 2026
Our scenario range runs from 2,812 KRW (bear case) to 5,741 KRW (bull case); at 6,580 KRW, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 23% below its 52-week high and 36% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at -30%, 067370 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: Growth Earnings (10,669 KRW) versus Growth DCF (893.60 KRW). Highest evidence: Growth DCF (80).
Notify me when 067370 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
Figures from reported company fundamentals · as of Jul 20, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 53 · Market factors (momentum, volatility) 42
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
SunBio,Inc., a biotech company, develops, produces, and sells biosimilar and biopharmaceutical products, and medical devices based on its technologies of pegylation worldwide. Its biosimilar products include PEG-filgrastim; and PEG-EPO and uricase which is in preclinical stage.
Full company description
SunBio,Inc., a biotech company, develops, produces, and sells biosimilar and biopharmaceutical products, and medical devices based on its technologies of pegylation worldwide. Its biosimilar products include PEG-filgrastim; and PEG-EPO and uricase which is in preclinical stage. The company offers MucoPEG, a medical device for treatment of dry mouth syndrome; and SynoGEL, a viscosupplement for arthritic Knee. Its preclinical stage biopharmaceuticals candidates target brain stroke and chronic anemia. It also manufactures and sells PEG derivatives. The company was founded in 1997 and is headquartered in Gunpo-si, South Korea.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2025 · reported fiscal years
SunBio,Inc., a biotech company, reported revenue of 13.7B KRW in FY2025 versus 7.4B KRW in FY2022, a compound +22.6%/yr. Reported net income was 2.8B KRW in FY2025, compounding +47.6%/yr from FY2022.
067370 screens 30% overvalued. Compare with Vertex Pharmaceuticals Incorporated →
Peer Group
Biotechnology · 601 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Biotechnology median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 20, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $486.03 | $278.78 | -43% |
| Regeneron Pharmaceuticals, Inc REGN | $664.45 | $594.40 | -11% |
| Samsung Biologics Co 207940 | 1,368,000 KRW | 1,091,384 KRW | -20% |
| Celltrion, Inc 068270 | 175,800 KRW | 76,325 KRW | -57% |
| WuXi Biologics (Cayman) Inc 2269 | HK$39.54 | HK$30.42 | -23% |
| Innovent Biologics, Inc 1801 | HK$86.70 | HK$19.66 | -77% |
| Sino Biopharmaceutical Limited 1177 | HK$5.26 | HK$3.36 | -36% |
| ALTEOGEN Inc 196170 | 276,500 KRW | 44,444 KRW | -84% |
| RemeGen Co 688331 | ¥134.02 | ¥26.99 | -80% |
| Biocon Limited BIOCON | ₹440.70 | ₹57.36 | -87% |
Compare SunBio,Inc., a biotech company, with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is SunBio,Inc., a biotech company, (067370) overvalued or undervalued?
What is the fair value of 067370?
What is the quality score of 067370?
What is the revenue of SunBio,Inc., a biotech company, (067370)?
What is the net profit margin of 067370?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track SunBio,Inc., a biotech company, and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.